Tarsus Pharmaceuticals, Inc.
TARS
$46.47
$2.906.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 291.38M | 316.95M | 323.58M | 298.52M | 227.44M |
| Total Receivables | 48.06M | 30.30M | 30.84M | 31.36M | 17.71M |
| Inventory | 2.62M | 2.85M | 2.20M | 4.04M | 3.11M |
| Prepaid Expenses | 14.65M | 7.02M | 5.97M | 6.80M | 7.87M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 356.71M | 357.12M | 362.59M | 340.72M | 256.13M |
|
|
|||||
| Total Current Assets | 356.71M | 357.12M | 362.59M | 340.72M | 256.13M |
| Net Property, Plant & Equipment | 2.87M | 4.20M | 4.21M | 3.47M | 3.35M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 8.33M | 8.57M | 3.67M | 3.77M | 3.87M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 6.09M | 3.42M | 3.38M | 1.32M | 1.29M |
| Total Assets | 376.99M | 376.30M | 376.84M | 349.28M | 265.49M |
|
|
|||||
| Total Accounts Payable | 27.74M | 26.82M | 26.65M | 19.14M | 17.77M |
| Total Accrued Expenses | 19.14M | 15.72M | 8.51M | 6.42M | 13.90M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 608.00K | 631.00K | 605.00K | 585.00K | 398.00K |
| Total Finance Division Other Current Liabilities | 33.12M | 22.70M | 15.80M | 16.38M | 4.87M |
| Total Other Current Liabilities | 33.12M | 22.70M | 15.80M | 16.38M | 4.87M |
| Total Current Liabilities | 80.61M | 65.87M | 51.57M | 42.53M | 36.94M |
|
|
|||||
| Total Current Liabilities | 80.61M | 65.87M | 51.57M | 42.53M | 36.94M |
| Long-Term Debt | 71.85M | 71.71M | 71.58M | 29.93M | 29.82M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | 1.24M | 1.45M | 1.61M | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | 1.75M |
| Total Liabilities | 152.46M | 138.82M | 124.60M | 74.07M | 68.50M |
|
|
|||||
| Common Stock & APIC | 584.57M | 574.24M | 566.10M | 555.66M | 441.65M |
| Retained Earnings | -360.21M | -337.10M | -313.68M | -280.39M | -244.66M |
| Treasury Stock & Other | 179.00K | 346.00K | -176.00K | -63.00K | -2.00K |
| Total Common Equity | 224.53M | 237.48M | 252.25M | 275.21M | 196.99M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 224.53M | 237.48M | 252.25M | 275.21M | 196.99M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 224.53M | 237.48M | 252.25M | 275.21M | 196.99M |
|
|
|||||
